The optimal definition and prediction nomogram for left ventricular remodelling after acute myocardial infarction

Sicheng Zhang1,2,3,4, Zheng Zhu5, Manqing Luo1,2,3,4

  • 1Department of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.

ESC Heart Failure
|July 25, 2023
PubMed

Insights

Left ventricular remodelling after myocardial infarction predicts poor outcomes. Defining remodelling by left ventricular ejection fraction (LVEF) is crucial for predicting mortality, and a new nomogram aids in identifying at-risk patients.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Medical Diagnostics

Background:

  • Left ventricular (LV) remodelling post-acute myocardial infarction (AMI) is linked to heart failure and mortality.
  • Lack of consensus on LV remodelling definitions hinders prognostic assessment.
  • Previous studies have not compared the prognostic value of different LV remodelling definitions.

Purpose of the Study:

  • To determine the optimal definition of LV remodelling after AMI.
  • To develop a predictive nomogram for identifying patients at risk of LV remodelling.
  • To create an online calculator for assessing LV remodelling risk.

Main Methods:

  • Prospective observational study of 829 AMI patients undergoing percutaneous coronary intervention.
  • Echocardiography at admission and 6 months to assess LV remodelling (defined by LVEDV, LVESV, or LVEF).
  • Lasso and multivariable logistic regression for nomogram development; AUC, calibration, and decision curve analyses for validation.

Main Results:

  • Incidences of LV remodelling were 24.85% (LVEDV), 28.71% (LVESV), and 14.60% (LVEF).
  • All definitions independently predicted composite endpoints, but only LVEF-defined remodelling predicted all-cause mortality (HR 2.78).
  • A 7-variable nomogram (including BP, HR, AMI type, stent length, NT-proBNP, troponin I, glucose) showed good predictive performance (AUC 0.766).

Conclusions:

  • LV remodelling, by various definitions, predicts long-term adverse outcomes in post-PCI AMI patients.
  • Left ventricular ejection fraction (LVEF) < 50% is the most suitable definition for predicting all-cause mortality.
  • The developed nomogram offers an accurate and effective tool for predicting post-infarct LV remodelling.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11